Interleukin-18 -137 G/C and -607 C/A polymorphisms and Alzheimer's disease risk: a meta-analysis
Jiaojiao Zhang1, Tingting Song2, Hua Liang1
1Department of Pathology, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, No.277, West Yanta Road, Xi'an, 710061, Shaanxi, People's Republic of China.
Abstract:
The -137 G/C and -607 C/A polymorphisms in interleukin-18 (IL-18) gene have been reported to be associated with Alzheimer's disease (AD) risk, but the results are inconclusive. Considering a single study may lack the power to provide reliable conclusion, we performed a meta-analysis to investigate the association between the IL-18 -137 G/C and -607 C/A polymorphisms and AD susceptibility. A comprehensive literature search of PubMed, Embase, China National Knowledge Infrastructure (CNKI) and Wanfang databases were conducted before September 1, 2015. The pooled odds ratio (OR) with 95 % confidence intervals (CIs) were calculated. Five eligible studies with a total of 1536 subjects were finally included in this meta-analysis. For the IL-18 -137 G/C polymorphism, a significantly decreased risk was detected in patients carrying the C allele of -137 G/C in all study subjects in allele model (C vs. G: OR = 0.816, 95 % CI = 0.680-0.980, p = 0.029). Moreover, stratification by ethnicity indicated markedly association between the -137 G/C C allele and AD risk in Asians. For the IL-18 -607 C/A polymorphism, a significantly decreased risk was found in patients carrying the A allele of -607 C/A in all study subjects in dominant model (AA + CA vs. CC: OR = 0.696, 95 % CI = 0.529-0.915, p = 0.010). However, the results suggested no significant association between the -607 C/A polymorphism and AD susceptibility when stratified by ethnicity. Our present meta-analysis suggests that the C allele carrier of IL-18 -137 G/C was associated with decreased risk for AD in Asians. Further well-designed case-control studies with larger sample size and more ethnic groups are needed to confirm these conclusions.
More Related Videos
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
